Engineered immune cells take aim at Hard-to-Treat cancers

This early-stage study is testing a new treatment called CEA-targeted CAR-T cells in people with advanced non-small cell lung cancer or breast cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells that carry a protein called CEA. The main goals are to check safety and find the best dose, while also seeing if the treatment can shrink tumors or slow disease progression.